The Latest Cardiac and Vascular News
Deal adds second FDA 510(k) cleared device to thrombectomy platform Easy-to-use, stand-alone, single session mechanical thrombectomy for removal of venous clot in highly attractive, rapidly growing and significantly under-penetrated market FDA 510(k) cleared (Dec. 2020) and CE Mark Certification (May 2021) 12-month follow-up data of 19-patient feasibility trial presented at […]
Monday, 6 July 20201. Vasorum Limited has announced the appointment of Bob Smouse M.D., F.A.C.R., as a non-executive director. Vasorum is a Dublin based, high-growth medical device business specializing in sophisticated devices used to close arterial punctures in vascular, cardiology, radiology, and neuro-radiology procedures. In February of this […]
Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced […]
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to twelve new employees whose employment commenced in June 2021 as a material inducement to […]
July 01, 2021 FDA 510k-cleared real-time 3D intracardiac echocardiography (ICE) catheter has potential to improve standard of care for structural heart disease and electrophysiology procedures Reduced need for general anesthesia accelerates workflows, increases efficiency, and broadens treatment options Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in […]
PFÄFFIKON, Switzerland, July 1, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced that it has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D. “We are extremely proud to welcome […]
WARRINGTON, Pa., July 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Diane Carman, Esq. as Senior Vice President and General Counsel, reporting to Craig Fraser, President and Chief Executive Officer. Ms. Carman […]
The RESTORE trial will test the safety and efficacy of the HARPOON™ Beating Heart Mitral Valve Repair System. New minimally invasive device could reduce pain, complications and recovery time for mitral valve repair surgery. Hoag is one of only 40 sites in the world selected for this trial. NEWPORT BEACH, […]
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes London, UK, 1 July 2021 – George Medicines, a late-stage drug development company focused […]
REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsi Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per month versus baseline Clinically important improvement in quality of life maintained even up to 12 months post-implantation Safety profile remains in line […]
